Kornimate/medical-research-clean huggingface dataset:
conventional versus 3d printing duplication techniques of complete denture

Conditions: Denture,Complete; Edentulous Alveolar Ridge

Summary: twenty completely edentulous patients with old, removable dentures with ill-fitting maxillary dentures, proper vertical dimension, and proper occlusion will be recruited for this trial. they will be rehabilitated with duplicated complete dentures manufactured by conventional and two different 3d-printed cad-cam complete removable dentures techniques. outcomes will be evaluated, including denture retention, which will be evaluated using a digital force gauge, and occlusal force distribution by using a t-scan.

the study will be conducted at the outpatient clinic of the oral and maxillofacial prosthodontics department, faculty of dentistry, ain shams university. this within-subject controlled clinical trial will involve twenty completely edentulous patients with old, ill-fitting maxillary complete dentures, who will be selected and recruited following approval by the research ethics committee of the faculty of dentistry, ain shams university (fdasu-rec). these patients will be rehabilitated with duplicated complete dentures produced through conventional methods and two distinct 3d-printed cad/cam techniques. group i: the duplication of a refitted complete removable denture will be performed using the conventional heat-cured technique. group ii: the refitted complete denture will be duplicated using a 3d-printed cad/cam technique, where the denture base will be printed separately with pink resin, and the teeth will be printed as a single unit in tooth-colored resin, followed by assembly of the two components. group iii: the refitted complete denture will be duplicated using a 3d-printed cad/cam technique, with the entire denture printed as a single unit in tooth-colored resin, and the denture flange veneered with pink resin. outcomes will be evaluated by measuring denture retention with a digital force gauge and occlusal force distribution using the t-scan system. the collected data will be recorded, tabulated, and subjected to statistical analysis using appropriate tests for group comparisons.

Eligibility criteria:
inclusion criteria: 1. patients with old complete dentures without lost vertical dimension. 2. patients with correct centric occluding relation. 3. the dentures should be esthetically and functionally satisfactory and exhibit reasonable retention and stability exclusion criteria: 1. the presence of ridge or soft tissue pathology. 2. diminished saliva production. 3. a history of medications affecting saliva quantity or quality. 4. patients with temporomandibular joint problems. 5. the presence of sever ridge undercut. 6. debilitated patients

Keywords: cad-cam complete dentures copying , denture
validation in french language of the questionnaire ears

Conditions: Chronic Low Back Pain

Summary: the main objective of this work is to validate in french the questionnaire ears, adapted to chronic low back pain. physical exercise is often recognized as necessary for primary and secondary prevention and treatment of chronic diseases. this is particularly true of chronic low back pain. it is therefore of paramount importance that compliance with such treatment be assessed to allow for readjustments, as well as drug treatment. no gold standard6-7 measured patient adherence to exercise programs until the creation of the ears in 2016 by e.godfrey and his team (exercise adherence rating scale, literally "joining physical exercise programs") ears is a reliable and validated psychometric assessment questionnaire that assesses adherence to prescribed physical exercise in chronic low back pain.

self-management of the patient to perform these exercises involves good collaboration with the care prescriber, leaving patients to manage and monitor their health. long-term adherence to care programs, including physical exercise, is paramount for these patients in order to maintain a beneficial long-term effect, which is the case in non-specific chronic low back pain. however, evidence shows that compliance levels following a physical exercise prescription are low, limiting the benefits this could bring. currently, ears is validated for chronic low back pain in its english version. to our knowledge and to the knowledge of the questionnaire's author, e.godfrey, there are no other studies that have examined the validation of ears in the french language for chronic low back pain. patients will be asked to complete a series of questionnaires after completing the non-opposition form. the management of non-specific chronic low back pain also requires evaluation through questionnaires, in accordance with the usual practices of the services participating in the study. no intervention will be taken.

Eligibility criteria:
inclusion criteria: * both sexes * adult (\>18 years old) * chronic low back pain evolving for at least 3 months * acceptance to participate in the study * patients affiliated to a social security scheme (beneficiary entitled) exclusion criteria: * patient under guardianship, or protection of justice. * patient in the incapacity to answer the questionnaire.

Keywords: chronic low back pain physical activity questionnaire adhesion
registry for accelerated partial breast irradiation with (sbrt) or (imrt)

Conditions: Breast Cancer

Summary: this is a registry study that will be used to evaluate external beam radiation therapy methods for the accelerated treatment of breast cancer. patients are being asked to take part in this registry because they have breast cancer and desire treatment with accelerated partial breast irradiation to be delivered by external beam methods.


Eligibility criteria:
inclusion criteria: * greater than or equal to 50 years old low to intermediate dcis tumor size \< or = to 2cm exclusion criteria: * brca positive lobular histology angiolymphatic invasion
a phaseⅱ study: sox vs sp in adjuvant chemotherapy after d2 surgery

Conditions: Gastric Cancer

Summary: to investigate the efficiency and safety of sox or sp adjuvant chemotherapy to phase ii and iii gastric cancer patients after d2 surgery. if sox is equal to sp in efficiency and less toxicity.


Eligibility criteria:
inclusion criteria: * histologically confirmed phase iii adenocarcinoma of gastric and esophageal-gastric junction ( ajcc 7th) * without previous treatment, including radiotherapy, chemotherapy and immunotherapy * hb≥90g/l,wbc 4×109/l-10×109/l,anc≥2×109/l,platelet≥100×109/l * creatinine≤1 unl * total bilirubin≤1.5 unl,ast(sgot),alt(sgpt) and alp≤2.5 unl * ecog score 0 - 2 * take chemotherapy for 8 weeks after surgery * older than 18 years * can be followed up, good compliance * can take medicine orally * having signed informed consent exclusion criteria: * combined disease lead to life expectancy less than 3 years * any evidence to show metastasis,including cancer cells in peritoneal fluid * inability to take oral medication for difficult to swallow, intestinal obstruction，active intestinal blooding or perforation * previous treatment,including cytotoxic chemotherapy, radio chemotherapy or immunotherapy ( except corticosteroid hormone） * operation within 4 weeks, or not recovered from last major operation * allergy with fluorouracil * allergy with platinum or any composition in research drugs * uncontrollable seizure disorder，central nervous system disease or mental disorders, and has clinical significance by judgement of researchers, or can influnce understanding of informed consent or compliance to take orally drugs * in the past 12 months, has clinical significant heart disease(active),such as symptomatic coronary heart disease, \> =stage ii congestive cardiac failure;congestive heart failure as nyha standard, or serious arrhythmias need take medicine( as appendix 10th),or myocardical infarction. * pregnancy， lactation， women in child-bearing period and her spouses reject to take effictive method to conraception * other previous malignancy within 5 years, except healed skin basal cell carcinoma and carcinoma in cervix * peripheral neuropathy\> grade 1 of ctcaev3, except the neural abnormality patients who only lose deep tendon reflex（dtrs）. * serious complicated infection or other complicated diseases and hard to controll. * as one of belowing: * anc \< 2×109/l * platelet\<100×109/l * total bilirubin\>1.5 unl * alat、asat \> 2.5 x uln * alp\> 2.5 x uln * any investigational agent within the past 28 days. that is the patient had jioned another trial.

Keywords: gastric cancer d2 surgery s-1 oxaliplatin cisplatin
a study of imc-001 in patients with metastatic or locally advanced tmb-h solid tumor

Conditions: TMB-H; Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors

Summary: the goal of this clinical trial is to determine the efficacy of imc-001 in metastatic or locally advanced tmb-h solid tumor patients.


Eligibility criteria:
inclusion criteria: 1. documented tmb-h:≥ 16 mut/mb, determined by the trusighttm oncology 500 ngs panel or oncominetm comprehensive assay plus 2. histologically or cytologically proven metastatic or locally advanced solid tumors.the participant must have at least one measurable tumor lesion per recist 1.1. 3. investigator has confirmation that participant's tumor tissue is available to be submitted to a central pathology laboratory. 4. adult age(as defined by respective country) 5. the nature of the study and voluntarily sign an icf 6. ecog 0 or1 7. prior systemic radiation therapy must be completed at least 4 weeks before the first dose of study drug. prior focal radiotherapy must be completed at least 2 weeks before the first dose of study drug. 8. at the time of the first dose of study drug at least 28 days since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to \< grade 2. 9. adequate hematologic function, hepatic function, and renal function 10. female participants must meet one of the following criteria: * postmenopausal (≥24 months, or ≥12 months with fsh \> 40 iu/l), * surgically incapable of bearing children (i.e., has had a hysterectomy or bilateral oophorectomy); or * females of childbearing potential must agree to use a reliable form of contraceptive during the study treatment period and for at least 90 days following the last dose of study drug. 11. male participants must agree to use barrier contraception (i.e., condoms) for the duration of the study and for at least 90 days after the last dose of study drug. 12. predicted life expectancy of at least 16 weeks. exclusion criteria: 1. previously treated with an anti-pd-l1 or anti-pd-1 antibody 2. known presence of symptomatic cns metastases 3. any active autoimmune disease or a documented history of autoimmune disease 4. apparent active and known viral infection with hiv, hepatitis b virus or hepatitis c virus 5. pregnant or lactating

Keywords: imc-001,imc-001-202,tmb-h
protection against visible light by dihydroxyacetone in erythropoietic protoporphyria

Conditions: Erythropoietic Protoporphyria

Summary: what is the visible light protective effect of dihydroxyacetone in individuals with erythropoietic protoporphyria? this will be tested in this randomized blinded placebo controlled study.


Eligibility criteria:
inclusion criteria: * diagnosed with erythropoietic protoporphyria * at least 18 years of age * obtainment of written informed consent exclusion criteria: * pregnant or breastfeeding * use of dihydroxyacetone at the treatment or placebo fields within the last two week * sun exposure of the treatment or placebo fields within the last two week * use of suncreen or other local treatment on the treatment or placebo fields during the study period (two days) * allergy to adhesive bandages, dihydroxyacetone or lotion

Keywords: dihydroxyaceton erythropoietic protoporphyria light protection protoporphyrin ix self-tanning skin
safety and immunogenicity of the candidate vaccine mva-mers-s_df-1 against mers

Conditions: MERS (Middle East Respiratory Syndrome)

Summary: the study will be a two center, randomized, double blind, placebo controlled study of the mva mers s_df-1 candidate delivered by i.m. injection. to evaluate the mers-s-specific antibody responses and safety profile induced by the two dosage levels of mva-mers-s_df-1 the data will be compared to a placebo control group.

this will be a phase ib, two-center study in approximately 160 healthy adults aged 18-55 years the study is separated in two parts: part a: the study starts with a single center open-label run-in phase of two dose levels (cohort 1 "low dose": 2x10\^7 pfu, cohort 2 "high dose": 2x10\^8 pfu) in 10 healthy subjects. 5 subjects will be allocated to each dose cohort and will receive immunization on day 0 and day 28. part b: two-center, randomized, double-blind, placebo-controlled, dose-finding study. this part is a double-blinded trial in approximately 150 healthy subjects. subjects will be allocated to two different dose cohorts and a placebo cohort; each receiving three vaccine injections.

Eligibility criteria:
inclusion criteria: 1. written informed consent form. 2. healthy male and female subjects aged 18-55 years. 3. no clinically significant acute health problems as determined from medical history and physical examination at screening visit. 4. body mass index 18.5 - 30.0 kg/m2 and weight \> 50 kg at screening. 5. non-pregnant, non-lactating female with negative pregnancy test. 6. males and females who agree to comply with the applicable contraceptive requirements of the protocol. exclusion criteria: 1. receipt of any vaccine from 2 weeks prior to each trial vac-cination (4 weeks for live vaccines) to 3 weeks after each trial vaccination. 2. receipt of vaccination against mers or mva immunizations.in the medical history. 3. known allergy to the components of the mva-mers-s_df-1 vaccine product. 4. evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product. 5. any confirmed or suspected immunosuppressive or immuno-deficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes. 6. any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child.

Keywords: mers-cov cepi viral vector vaccine
formative study of tailored survivor health promotion

Conditions: Colorectal Cancer

Summary: the overall goal of this study is to explore colorectal cancer patients' concerns and interest about their health and behavior changes post treatment. investigators will conduct formative research, which includes qualitative interviews, to assess the issues that cancer survivors are willing to work on as they transition out of active treatment. the specific aims are as follows: aim 1: use qualitative interview methods to describe the taxonomy of domains health promotion and illness prevention behavior changes for which colorectal cancer survivors need new information, skills training and support. aim 2: explore colorectal cancer patients' perceptions of their post treatment functional status. aim 3: explore the impact of cancer, treatment, and co-morbidities on colorectal cancer patients' health goals and functional status.

study procedures: if you agree to take part in this study, you will be asked to fill out a questionnaire about the your current health status, social support and goals. after completing the questionnaire, you will have an interview with a research assistant. the interview will be audio recorded. you will be asked about goals you have for your health, what you are doing to reach those goals, resources you would like to receive, and challenges you faced since completing your treatment. your name and any of your other personal identifying information will not be linked to or collected with any of your responses. all audio tapes will be destroyed at the end of the study. length of study : the total time of participation for this study is about 45 minutes. this is an investigational study. up to 45 patients will be enrolled in this multicenter study. up to 15 will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. patient with stage iib or iii colorectal cancer. 2. men and women within 1 year of ending primary treatment for colorectal cancer. 3. over 18 years of age. 4. must be able to read and write english. 5. must be able to understand and provide written informed consent. exclusion criteria: 1) patients who have had previous treatment for cancer before treatment at m.d. anderson, kelsey-seybold, and the va medical center.

Keywords: colorectal cancer cancer survivorship study questionnaires survivorship survivor health health promotion behavior changes computer-assisted intervention program
an open-label, single-center study evaluating the effect of systane balance on video ocular protection index (opi) and blink patterns in patients diagnosed with dry eye

Conditions: Dry Eye Syndrome

Summary: the purpose of this study is to evaluate the effect of acute and repeat dosing of systane balance on video ocular protection index (opi) and blink patterns in a population of dry eye patients.


Eligibility criteria:
inclusion criteria: * patients must have history of mild-moderate dry eye with use of (or desire to use) eye drops in past 6 months exclusion criteria: * patients cannot wear contact lenses within 1 week prior nor during the study, and cannot have a history of hypersensitivity to any component of systane balance.
vaginal microbiome and the development of vulvovaginal graft versus host disease

Conditions: Bone Marrow Transplant Complications

Summary: allogeneic stem cell transplantation (also termed "bone marrow transplantation") involves transferring stem cells from a healthy person (the donor) to the patient, after high-intensity chemotherapy or radiation, given to destroy any remaining cancer cells in the body. when a transplant is successful, the donor stem cells replace the original cells in the bone marrow. it may provide the only long-term cure of the patient's disease. of transplant-related complications, graft-versus-host disease (gvhd) is one of the most important complications. gvhd arises from donor immune cells, that identify the recipient's (the patien's) cells as foreign and attack them. approximately half of women undergoing transplantation will experience gvhd involving the genitalia (i.e., the vulva and vagina), termed vulvovaginal gvhd (vv-gvhd). vv-gvhd may cause irreversible anatomical changes, including complete vaginal obliteration, and not surprisingly, it has a severe impact on patients' quality of life and sexual function. this complication is unpredictable and non-preventable by the usual immunosuppressive treatment given to patients. frequent gynecological examinations and prolonged follow-up of transplanted women are needed, to allow early diagnosis and prevention of harmful results of vv-gvhd. this follow-up adds inconvenience and anxiety to the patients. the suggested study aims to evaluate a possible association between vaginal microorganisms (the "microbiome") to the progress of vv-gvhd. finding such association may allow prediction of vv-gvhd progress, a better understanding of the development of vv-gvhd and a potential to develop interventions for the treatment and prevention of vv-gvhd.


Eligibility criteria:
inclusion criteria: * age≥18 * candidate for allogeneic stem cell transplantation * ability to sign an informed consent exclusion criteria: - patient does not approve sample collection
polyethyleneglycol3350 vs tegaserod in treatment of patients with chronic constipation

Conditions: Constipation

Summary: the purpose of this study is to compare the safety and efficacy of extended polyethyleneglycol3350 use to tegaserod in patients with chronic constipation.


Eligibility criteria:
inclusion criteria: * male or female outpatients at least 18 years of age * constipated according to rome i criteria * if female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, double- barrier method, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study * are otherwise in good health, as judged by a physical examination * in the investigator's judgment, patient is mentally competent to sign an instrument of informed consent exclusion criteria: * patients with heme positive stool at screening that is not associated with hemorrhoids or anal fissures. * patients with hypo- or hyperthyroidism as determined by medical history. * patients with severe renal impairment. * patients with moderate or severe hepatic impairment. * patients with known or suspected perforation or obstruction. * history of gastric retention, inflammatory bowel disease, bowel resection, or colostomy. * patients with symptomatic gallbladder disease, suspected sphincter of oddi dysfunction, or abdominal adhesions. * patients with a known history of organic cause for their constipation. * patients currently taking, or planning to take any of the following medications that are known to effect bowel habits: * antidiarrheals * antacids containing magnesium or aluminum salts * anticholinergics * antispasmodic agents * erythromycin and other macrolides * octreotide * lotronex, zofran, or other 5-ht3 antagonists * zelnorm, or other 5-ht4 agonists * opiods/narcotic analgesics * prokinetics * serotonin re-uptake inhibitors or tricyclic antidepressants * calcium antagonists * patients who are breastfeeding, pregnant, or intend to become pregnant during the study. * female patients of childbearing potential who refuse a pregnancy test. * patients with a known allergy to tegaserod (or any of its excipients) or polyethyleneglycol. * patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures. * patients who, within the past 30 days have participated in an investigational clinical study. * patients that have undergone a colonoscopy within 30 days of screening * patients that are currently taking, or have previously been treated with polyethyleneglycol3350 or tegaserod.